STAT+: Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices

In his ongoing quest to probe pharmaceutical industry tax practices, the head of the U.S. Senate Finance Committee is pressing Merck and Abbott Laboratories to provide detailed financial information that so far, the companies have refused to submit.

In letters sent on Wednesday, Sen. Ron Wyden (D-Ore.) noted that, since the 2017 passage of a tax law lowered tax rates for large pharmaceutical companies headquartered in the U.S., both Merck and Abbott paid substantially less than the 21% corporate tax rate. Merck paid 11% last year, while Abbott paid 13.9%. (Here’s the letter to Merck, and the letter to Abbott).

Continue to STAT+ to read the full story…